Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2021 call → NO我们根据提供的电话会议记录,判断管理层是否描述了“同类连续业务以越来越大的规模到来”的现象。即,公司现在获得的交易、订单、合同、项目、客户、站点或项目是否比不久前的同类业务更大、更广或更长。 在记录中,管理层讨论了vadadustat的上市准备、市场机会、商业团队等。他们提到“我们相信vadadustat有潜力成为美国首个同类HIF-PHI”,“这是一个比我们几个月前预期的更大的市场机会”。但这是关于市场机会的规模,而不是关于公司自身业务单元(如合同、订单)的规模递增。他们提到“我们正在为成功上市做准备”,但未提及具体交易或合同的规模递增。 关于Auryxia,他们提到收入增长,但这是产品收入,不是新合同或订单的规模。他们提到“我们继续预期Auryxia在2021年实现年度收入增长”,但未提及单个订单或客户规模变大。 关于vadadustat的上市,他们提到“我们相信快速采用也可能在美国发生,因为透析市场独特的报销模式TDAPA”,但这是关于报销,不是关于业务单元规模。 没有提到“新客户以更大规模进入”、“订单规模增加”、“合同期限延长”等。他们提到“我们正在准备成功上市”,但未提及具体交易规模。 因此,没有证据表明管理层描述了同类业务单元规模递增的现象。他们谈论的是市场机会、产品潜力、团队准备,但未提及公司自身获得的交易或项目规模变大。 所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.